Topical carbonic anhydrase inhibitors

Current Opinion in Ophthalmology

Volumn 8, Issue 2, 1997, Pages 2-6

  Talluto, Donna M ^a   Wyse, Tamara B ^a   Krupin, Theodore ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; PILOCARPINE;

CORNEA EDEMA; CORNEA ENDOTHELIUM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 0030740943     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199704000-00002     Document Type: Short Survey

References (52)

1. Becker B: Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol 1954, 37:13-15.
2. Hageman GS, Zhu XL, Waheed A, Sly WS: Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci U S A 1991, 88:2716-2720.
3. Wolfensberger TJ, Chiang R, Takeuchi A, Marmor MF: Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Invest Ophthalmol Vis Sci 1995, 36(suppl):4239
4. Dobbs PC, Epstein DL, Anderson JP: Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci 1979, 18:867-870.
5. Wistrand PJ, Garg LC: Evidence of high-activity C type of carbonic anhydrase inhibitor in human ciliary processes. Invest Ophthalmol Vis Sci 1979, 18:802-806.
6. Wistrand PJ: Distribution and function of carbonic anhydrase (CA) isoenzymes in the human eye: relevance for the design of topical carbonic anhydrase inhibitors. Exp Eye Res 1992, 55(suppl):1B5.
7. Sugrue MF, Funk HA, Lazarides E, Mallorga P, O'Neill-Davis LA, Ritter PJ: Evidence for a role of membrane bound carbonic anhydrase in intraocular pressure in rabbits. Invest Ophtalmol Vis Sci 1994, 35(suppl):1400.
8. Maren TH, Wymis GC, Wistrand PJ: Properties of carbonic anhydrase (CA) IV, the membrane-bound enzyme in secretory tissues. Invest Ophthalmol Vis Sci 1993, 34(suppl):930.
9. Higginbotham EJ, Kass MA, Lippa EA: MK-927: a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1990, 108:65-68.
10. Mallorga P, Reiss ER, Ponticello GS, Baldwin JJ, Sugrue MF: Binding of the carbonic anhydrase inhibitor MK-927 to ocular pigment. Invest Ophthalmol Vis Sci 1989, 30(suppl):445.
11. Bron A, Lippa EA, Gunning F: Multiple dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927. Arch Ophthalmol 1991, 109:50-53.
12. Lippa EA, Sherwood M, Laibovitz R: MK-417 vs timolol: comparative activity. Invest Ophthalmol Vis Sci 1990, 31(suppl):232.
13. Lippa EA: Topical carbonic anhydrase inhibitors. In The Carbonic Anhydrases: Cellular Physiology and Molecular Genetics. Edited by Dodgson SJ. New York: Plenum Press; 1991:171-181.
14. Maren T: The development of topical carbonic anhydrase inhibitors. J Glaucoma 1995, 4:49-62. Excellent historic and pharmacologic review by the developer of topically active CAIs.
15. Maren TH, Jankowska L, Sanyal G, Edelhauser HF: The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 1983, 36:457-480.
16. Lippa EA: Carbonic anhydrase inhibitors. In The Glaucomas. Edited by Ritch R, Shields MB, Krupin T. St. Louis: Mosby; 1996:1463-1481. Excellent synopsis of published and unpublished clinical studies on topical CAIs, including dorzolamide.
17. Lippa EA, Schuman JS, Higginbotham EJ, et al.: MK-507 vs sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991, 98:308-312.
18. Wilkerson M, Cyrlin M, Lippa E, et al.: Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibrtor. Arch Ophthalmol 1993, 111:1343-1350.
19. Lippa EA, Carlson LE, Ehinger B: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992, 110:495-499.
20. Strahlman E, Tipping R, Vogel R, The Dorzolamide Dose-Response Study Group. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996, 122:183-194. A large, multinational, masked, prospective study showing that 2% dorzolamide produces a greater reduction in intraocular pressure than 0.7% dorzolamide when given three times daily for 1 year.
21. The MK-507 Clinical Study Group: Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J Glaucoma 1995, 4:6-10. A 1-year, Japanese, multicenter, open-label study on the effects of topical 1% dorzolamide given three times daily.
22. Meyer JL, Samples JR: Efficacy of dorzolamide in glaucoma subpopulations including pediatric and secondary glaucomas. Invest Ophthalmol Vis Sci 1996, 37(suppl):1099.
23. Donohue EK, Wilensky JT, Nail C, Hillman DS, Rhode JP: Relative efficacy of dorzolamide by iris color. Ophthalmology 1995, 102(suppl):160.
24. Hutzelmann J, Snyder E, Tipping R, Adamsons I: Comparison of the IOP lowering effect of 2.0% dorzolamide T.I.D. (Trusopt) in patients with light and dark irides. Invest Ophthalmol Vis Sci 1996, 37 (suppl):1101.
25. Bourgeois H, Bron A, Lippa E, et al.: 2% L-671,152: multiple-dose activity bid. Invest Ophthalmol Vis Sci 1990, 31(suppl):233.
26. Robison MY, Gamero GE, Harmon H, Goldsmith LJ. Fechtner RD, Zimmerman TJ: The effect of nasolacrimal occlusion on the duration of action of dorzolamide 2%. Invest Ophthalmol Vis Sci 1996, 37(suppl):1101.
27. Dahlen K, Epstein DL, Grant WM, Hutchmson BT, Prien EL, Krall JM: A repeated dose-response study of methazolamide in glaucoma. Arch Ophthalmol 1978, 96:2214-2218.
28. Maren TH: A comparison between topical and oral sulfonamides in treatment of elevated ocular pressure in man. Invest Ophthalmol Vis Sci 1992, 33(suppl): 1246.
29. Serle JB, Podos SM, Lippa EA, Klotzbuecher CM: Compassionate case usage of dorzolamide (MK-507) in 16 glaucoma patients. Invest Ophthalmol Vis Sci 1994, 35(suppl):2177.
30. Kitazawa Y, Azuma I, Araie M, Shirato S: Topical dorzolamide hydrochloride can be a substitute for oral carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 1994, 35(suppl):2177.
31. Fechtner RD, Robison MY, Gamero GE, Goldsmith LJ, Zimmerman TJ: A comparison on the efficacy of dorzolamide 2% and oral carbonic anhydrase inhibitors in clinical practice. Invest Ophthalmol Vis Sci 1996, 37(suppl):201.
32. Sonty SS, Sonty S, Viana M: The comparative prophylactic effect of topical dorzolamide and oral acetazolamide to prevent post cataract surgery ocular pressure rise. Invest Ophthalmol Vis Sci 1996, 37(suppl):1119.
33. Strahlman E, Tipping R, Vogel R, Group IDS: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995, 113:1009-1016. A double-masked, multinational study showing that monotherapy with 2% dorzolamide given three times daily is similar to 0.5% betaxolol given twice daily. Adding twice-daily 2% dorzolamide to timolol or betaxolol therapy produces an additional reduction in intraocular pressure.
34. Rosenberg LF, Krupin T, Tang L, Hong P, Ruderman J: Additivity of systemic acetazolamide and topical dorzolamide for reduction of intraocular pressure and aqueous humor production. Ophthalmology 1997, in press. Topical 2% dorzolamide and oral acetazolamide do not have an additive effect on intraocular pressure or on decreased aqueous humor formation (fluorophotometry).
35. Wang R, Serle JB, Podos SM, Sugrue MF: MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol 1991, 109:1297-1299.
36. Wistrand PJ, Schenholm M, Lonnerholm G: Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthalmol Vis Sci 1986, 27:419-428.
37. Sugrue MF, Waheed A, Sly WS: A study of the in vitro inhibition of carbonic anhydrase isoenzymes I, II, and IV. Invest Ophthalmol Vis Sci 1993, 34(suppl):930.
38. Biollaz J, Munafo A, Buclin T, et al.: Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995, 47:453-460. Topical dorzolamide is absorbed systemically and is taken up in erythrocytes with an elimination half-life of 120 days. Significant metabolic and renal effects are not seen.
39. Sonty SP, Sonty S, Viana M: The additive ocular hypotensive effect of topical 2% dorzolamide on glaucomatous eyes on topical beta blocker therapy. Invest Ophthalmol Vis Sci 1996, 37(suppl):1100.
40. Nardin G, Lewis R, Lippa EA: Activity of the topical CAI MK-507 BID when added to timolol BID. Invest Ophthalmol Vis Sci 1991, 32(suppl):1579.
41. Strohmaier K, Snyder E, Adamsons I: Long-term safety and efficacy of Cosopt, a fixed combination of dorzolamide and timolol. Invest Ophthalmol Vis Sci 1996, 37(suppl):1102.
42. Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM: Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995, 4:306-313. Dorzolamide, 2%. twice daily and pilocarpine, 2%. four limes daily are equally effective in decreasing intraocular pressure when added to topical timolol therapy. Self-reported quality-of-life measurements are more affected by pilocarpine (miotic) than by timolol.
43. Strahlman EL, Tipping RW, Clineschmidt CM: A controlled clinical trial comparing dorzolamide (MK-507) and pilocarpine as adjunctive therapy to timolol. Ophthalmology 1994, 101(suppl):129.
44. Donohue E, Wilensky JT: Trusopt, a topical carbonic anhydrase inhibitor. J Glaucoma 1996, 5:68-74. Excellent review article on the clinical efficacy and side effects of dorzolamide.
45. Samuel F, Katz LJ, Cantor LB, Hoop J, Azuara BA: The short-term effect of topical dorzolamide compared with placebo on perimetry testing in normal subjects. Invest Ophthalmol Vis Sci 1996, 37(suppl):830.
46. Brechue WF, Maren TH: IOP reduction following topical carbonic anhydrase inhibition (CAI) is affected by drug ionization. Invest Ophthalmol Vis Sci 1992, 33(suppl):1117.
47. Maren TH, Bar-llan A, Conroy CW, Brechue WF: Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route. Exp Eye Res 1990, 50:27-36.
48. Quinones RA, Wilensky JT, Viana M, Alvi N: Effect of dorzolamide on corneal thickness in humans. Invest Ophthalmol Vis Sci 1996, 37(suppl):1098.
49. Konowal A, Epstein RJ, Dennis RF, Brown SVL: Irreversible corneal decompensation in patients treated with topical dorzolamide. Invest Ophthalmol Vis Sci 1996. 37(suppl):79.
50. Lucci MS, Tinker JP, Weiner IM, DuBose TD: Function of proximal tubule carbonic anhydrase defined by selective inhibition. Am J Physiol 1983, 245:F443-449.
51. Buclin T, Biollaz J, Lippa EY, et al.: Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clin Pharmacol Ther 1991, 49:665-673
52. Gervasoni JP, Lippa EY, Biollaz J, et al.: Absence of metabolic effects of a methyl-thienothiopyran-2-sulfonamide, a new carbonic anhydrase inhibitor (CAI) during a 2-week ocular administration. Clin Pharmacol Ther 1991, 49:192.